TOKYO, Dec 11, 2023 – (JCN Newswire via SeaPRwire.com) – Eisai and Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside of the United States and Canada) today announced that the Phase 3 LEAP-001 trial evaluating LENVIMA®, the orally available multiple receptor tyrosine kinase inh […]